Orexo delays Actavis generic until at least 2019

17-11-2016

Orexo delays Actavis generic until at least 2019

Oleksii Fedorenko / shutterstock.com

The US District Court for the District Court of Delaware has ruled in favour of Sweden-based pharmaceutical company Orexo in a patent battle against Actavis over Zubsolv (buprenorphine and naloxone).


Orexo, Actavis, patent, Zubsolv, ANDA, US District Court for the District Court of Delaware, generic

LSIPR